Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9711302 | 0.82 | TDP1 (0.47) | TSHRSMN1; SMN2TDP1ALDH1A1HSD17B10 | |
| SCHEMBL7229176 | 0.72 | MAPT (0.38) | TSHRSMN1; SMN2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL9336377 | 0.67 | — | — | |
| SCHEMBL9353183 | 0.67 | PDE7A (0.36) | SMN1; SMN2TDP1ALDH1A1RECQL | |
| SCHEMBL7226114 | 0.65 | SMN1; SMN2 (0.41) | SMN1; SMN2TDP1ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL9711236 | 0.65 | TDP1 (0.40) | TSHRSMN1; SMN2TDP1ALDH1A1HSD17B10 | |
| SCHEMBL9711273 | 0.65 | KMT2A (0.37) | TSHRSMN1; SMN2TDP1ALDH1A1RECQL | |
| SCHEMBL9350811 | 0.64 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL9740135 | 0.64 | TSHR (0.45) | TSHRSMN1; SMN2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL9194581 | 0.64 | TDP2 (0.40) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5153227-A | Treatment of diabetes and galactosemia complications | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-10-06 | — | — | US | disclosed |